FDA Clears Ultragenyx Drug Application for GNE Myopathy

Ultragenyx has received FDA clearance for its Investigational New Drug (IND) application for UX016, a novel sialic acid prodrug targeting GNE myopathy. This marks a significant step forward in developing a new treatment for this rare neuromuscular disorder. The program will be externally funded through a venture philanthropy agreement, with Phase 1/2 studies slated to commence soon. This innovative approach to funding aims to accelerate the development timeline and bring potential relief to patients suffering from GNE myopathy.